REG - CVS Group plc - Non-Executive Director Changes

CVSAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY9811Xa&default-theme=true

RNS Number : 9811X  CVS Group plc  25 March 2026

For Immediate
Release
                       25 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Non-Executive Director Changes

 

CVS, the UK listed veterinary group and a leading provider of veterinary
services, is pleased to announce the appointment of Helen Keays and Jane
Bednall as Independent Non-Executive Directors with effect from 1 April 2026,
the retirement of Deborah Kemp with effect from 30 June 2026 and a change in
Chair of the Group's Nomination Committee.

 

Retirement of Deborah Kemp

Deborah Kemp, who joined the board in January 2018 and who is presently Senior
Independent Director and Chair of the Remuneration Committee will retire and
step down from the Board and all board committees on 30 June 2026.

 

Appointment of Helen Keays

Helen Keays is presently an Independent Non-Executive Director and Chair of
the Remuneration Committee at Nichols plc following an executive career in
consumer-facing multi-site businesses across retail, mobile telecommunications
and retail financial services.  Helen has worked at Vodafone plc, latterly as
General Manager of Singlepoint, and previously at Sears plc. Helen has
previously been an Independent Non-Executive Director of The Restaurant Group,
Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli
Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive
Director and Remuneration Committee Chair and will add value to the board
through her expertise in people development, consumer marketing and CRM.

 

From the date of her appointment, Helen Keays will become Chair Designate of
the Remuneration Committee and will also become a member of the Group's Audit
and Risk Committee and Nomination Committee. Helen will formally become Chair
of the Remuneration Committee with effect from 1 July 2026.

 

Appointment of Jane Bednall

Jane Bednall is presently an Independent Non-Executive Director of Fuller
Smith & Turner plc and Independent Non-Executive Director and Chair of the
Remuneration, People and Culture Committee for The Kings Cross Group,
appointed on behalf of AustralianSuper, Australia's largest pension fund. This
follows an executive career in senior leadership roles at British Airways,
InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where
she was Chief Marketing Officer and formerly Managing Director of Retail
Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc
and Smart Energy GB. Jane will add value to the board through her experience
in multi-site retail and leisure businesses and her expertise in branding,
consumer behaviour and insights.

 

From the date of her appointment, Jane will become a member of the Group's
Remuneration Committee, Audit and Risk Committee and Nomination Committee.

 

Change in Nomination Committee Chair

David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the
Nominations Committee with effect from 1 April 2026.

 

David Wilton, CVS Chair commented:

 

"On behalf of the board, I am delighted to welcome Helen Keays and Jane
Bednall to CVS and I look forward to working with them. Helen and Jane will
strengthen the board through their extensive knowledge and experience in
developing consumer propositions and in marketing across a range of client
facing businesses.

 

"I would also like to record my profound thanks to Deborah Kemp for her
support and for the significant contribution she has made to CVS over the past
nine years.  Deborah joined the Board in January 2018 as Non-Executive
Director and has served as Senior Independent Director, Remuneration Committee
Chair, Employee Engagement Director and, for a period of six months, Interim
Chair.  Deborah has played an important governance role in support of the
Group's considerable expansion and will be missed."

 

The Company confirms that there is no further information about Helen Keays
or Jane Bednall requiring disclosure under paragraphs 6.4.8R (1) to (6) of
the FCA UK Listing Rules.

 

ENDS

 

Contacts

CVS Group
plc
                via Camarco

Richard Fairman, Chief Executive Officer

Scott Morrison, Group Legal Counsel and Company Secretary

 

Camarco (Financial
PR)

Ginny
Pulbrook
 
 cvsg@camarco.co.uk (mailto:cvsg@camarco.co.uk)

Tilly Butcher
 
                                +44 (0)20 3757 4980
(tel:+442037574980)

Letaba Rimell
 

 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk) )

CVS Group is a leading provider of veterinary services, operating in the UK
and Australia, listed on the Main Market of the London Stock Exchange.  CVS
is focused on providing high-quality clinical services to its clients and
their animals, with outstanding and dedicated clinical teams and support
colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and
3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEAEFLEMSESD



            Copyright 2019 Regulatory News Service, all rights reserved